UBS Group
CRDL

UBS Group’s Cardiol Therapeutics CRDL Stock Holding History

UBS Group’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6K Sell
8,609
-7,940
-48% -$8.15K ﹤0.01% 8290
2025
Q4 		$15.8K Sell
16,549
-36,941
-69% -$38.7K ﹤0.01% 7949
2025
Q3 		$57.2K Sell
53,490
-85,754
-62% -$104K ﹤0.01% 7471
2025
Q2 		$189K Sell
139,244
-358,613
-72% -$417K ﹤0.01% 6763
2025
Q1 		$483K Buy
497,857
+263,039
+112% +$323K ﹤0.01% 5876
2024
Q4 		$301K Buy
234,818
+232,168
+8,761% +$391K ﹤0.01% 6199
2024
Q3 		$5.25K Buy
2,650
+150
+6% +$311 ﹤0.01% 8077
2024
Q2 		$5.05K Sell
2,500
-281
-10% -$596 ﹤0.01% 8029
2024
Q1 		$5.03K Sell
2,781
-2,930
-51% -$3.95K ﹤0.01% 7566
2023
Q4 		$4.82K Buy
5,711
+3,151
+123% +$2.68K ﹤0.01% 7822
2023
Q3 		$2.29K Buy
2,560
+60
+2% +$57 ﹤0.01% 7731
2023
Q2 		$2.23K Sell
2,500
-18,046
-88% -$11.9K ﹤0.01% 7787
2023
Q1 		$10K Buy
20,546
+9,535
+87% +$5.64K ﹤0.01% 7616
2022
Q4 		$5.62K Buy
11,011
+9,011
+451% +$5.49K ﹤0.01% 9153
2022
Q3 		$2K Sell
2,000
-3,511
-64% -$4.28K ﹤0.01% 9704
2022
Q2 		$7K Sell
5,511
-3,295
-37% -$4.69K ﹤0.01% 8465
2022
Q1 		$13K Buy
8,806
+3,439
+64% +$5.67K ﹤0.01% 8035
2021
Q4 		$10K Buy
+5,367
New +$14.8K ﹤0.01% 8768

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's CRDL Position: Q1 2026 in Review

UBS Group reduced its Cardiol Therapeutics (CRDL) stake by 48% in Q1 2026, selling an estimated $8.15K and leaving 8,609 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8290.

UBS Group first reported a position in CRDL in Q4 2021 and has held it in 18 quarters since. The position peaked at $483K in Q1 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • UBS Group held 8,609 shares of Cardiol Therapeutics worth $11.6K as of Q1 2026.
  • UBS Group sold 7,940 Cardiol Therapeutics shares in Q1 2026, an estimated $8.15K.
  • Cardiol Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8290 holding.
  • UBS Group first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • UBS Group's Cardiol Therapeutics position peaked at $483K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.